---
url: https://www.servicesaustralia.gov.au/psoriasis-severe-chronic-plaque-psoriasis
title: Psoriasis - severe chronic plaque psoriasis - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:41.256Z
source: servicesaustralia.gov.au
---
# Psoriasis - severe chronic plaque psoriasis

The PBS subsidises biological medicines for patients with severe chronic plaque psoriasis.

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 arrangements](#a2)
-   [Treatment specifics](#a3)
-   [Authority applications](#a4)
-   [More information](#a5)

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with biological medicines under the _National Health Act 1953_, section 85 and section 100 for patients with severe chronic plaque psoriasis.

Where the term **biological medicine** appears, it refers to:

-   adalimumab
-   bimekizumab
-   etanercept
-   guselkumab
-   infliximab
-   ixekizumab
-   risankizumab
-   secukinumab
-   tildrakizumab
-   ustekinumab.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home;jsessionid=1dlcoha0l4vz2eo3rw03twopu) on the PBS website outlines the restrictions for prescribing biological medicines.

## Section 100 arrangements

### Infliximab IV

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:

-   an approved private hospital
-   a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

## Treatment specifics

To be eligible for PBS-subsidised treatment with biological medicines, patients must be treated by a dermatologist.

### PASI calculation forms

[PASI calculation and body diagram - whole body form](/pb115?context=20)

[PASI calculation and body diagram - face, hand and foot form](/pb114?context=20)

## Authority applications

### Patients 18 years of age or older

#### Applying for initial treatment

Please note: You don’t need to complete this application in writing when you request [PBS authority online](/apply-for-pbs-authority?context=20#accordion1).

Applications for initial authority approval to prescribe PBS-subsidised biological medicines to treat severe chronic plaque psoriasis can be made:

-   using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   in writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   in writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [severe chronic plaque psoriasis - initial authority application form](/pb112?context=20)
-   relevant attachments.

#### Applying for change or recommencement of treatment

Please note: You don’t need to complete this application in writing when you request [PBS authority online](/apply-for-pbs-authority?context=20#accordion1).

Applications to change or recommence authority approval to prescribe PBS-subsidised biological medicines to treat adult patients with severe chronic plaque psoriasis can be made:

-   using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   in writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   in writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [severe chronic plaque psoriasis - change or recommencement authority application form](/pb263?context=20)
-   relevant attachments.

#### Applying for continuing treatment - excluding infliximab SC

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

Applications for continuing authority approval to prescribe PBS-subsidised biological medicines to treat adult patients with severe chronic plaque psoriasis can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   in writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   in writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [severe chronic plaque psoriasis - continuing authority application form](/pb113?context=20)
-   relevant attachments.

After we approve the first application for continuing treatment, subsequent continuing treatments with PBS-subsidised biosimilar brands of biological medicines are Authority Required (Streamlined). You don’t need authority approval from us for the listed quantity and repeats.

#### Applying for continuing treatment - infliximab SC

Continuing PBS-subsidised treatment with infliximab SC is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.

### Patients under 18 years

#### **Adalimumab and u**stekinumab

##### **Applying for initial, change or recommencement of treatment**

Please note: You don’t need to complete this application in writing when you request [PBS authority online](/apply-for-pbs-authority?context=20#accordion1).

Applications for initial, change or recommencement authority approval to prescribe PBS-subsidised adalimumab or ustekinumab to treat patients under 18 years with severe chronic plaque psoriasis can be made:

-   using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   in writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   in writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [severe chronic plaque psoriasis paediatric - adalimumab or ustekinumab - initial, change or recommencement authority application form](/pb320?context=20)
-   relevant attachments.

#### Applying for continuing treatment

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

Applications for continuing authority approval to prescribe PBS-subsidised adalimumab or ustekinumab to treat patients under 18 years with severe chronic plaque psoriasis can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   in writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   in writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [severe chronic plaque psoriasis paediatric - adalimumab or ustekinumab - continuing authority application form](/pb319?context=20)
-   relevant attachments.

After we approve the first application for continuing treatment, subsequent continuing treatments with PBS-subsidised adalimumab or biosimilar brand of ustekinumab are Authority Required (Streamlined). You don’t need authority approval from us for the listed quantity and repeats.

#### Etanercept

Applications for initial, change, recommencement, or re-treatment authority approval to prescribe PBS-subsidised etanercept to treat patients under 18 years with severe chronic plaque psoriasis can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

Completion of the course of PBS-subsidised treatment with etanercept is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.

[

Severe chronic plaque psoriasis toxicity and severity descriptors

Toxicity and severity descriptors for treatments required to be trialled before accessing PBS-subsidised biological medicines to treat severe chronic plaque psoriasis in adults.


](/severe-chronic-plaque-psoriasis-toxicity-and-severity-descriptors?context=20)
